UNASSIGNED: All consecutive patients operated with a Salto XT revision prosthesis underwent clinical and radiologic examinations preoperatively and after 3, 12, 24, and 60 months. Complications and reoperations are described, and changes in patient-reported outcome measures and clinical scores are reported.
UNASSIGNED: Thirty patients were operated with a Salto XT revision prosthesis between March 2014 and March 2017. Three of these were revised (1 to a fusion and 2 to a new prosthesis), and 3 patients were reoperated with screw removal. A concurrent subtalar fusion was performed on 13 patients, and there was 1 case of likely nonunion after these procedures, but no reoperations. The mean AOFAS score increased from 39.2 (95% CI 30.8-47.5) preoperatively to 75.1 (95% CI 67.3-82.9) after 5 years, and the mean improvement was 34.2 points (95% CI 23.8-44.6). Mean EQ-5D increased from 0.36 (95% CI 0.30-0.42) preoperatively to 0.74 (95% CI 0.64-0.85) after 5 years, an improvement of 0.34 (95% CI 0.19-0.49). Radiolucent lines were present in all but 3 patients. Five-year prosthesis survival was 93% (83.6-100).
UNASSIGNED: This is the first study to present medium-term results of this implant. We found good improvement in outcome scores and good implant survival, but also a high prevalence of radiolucent lines.
■所有接受SaltoXT翻修假体手术的患者在术前和术后3、12、24和60个月接受临床和放射学检查。描述了并发症和再次手术,并报告患者报告的结局指标和临床评分的变化.
■在2014年3月至2017年3月期间,30例患者接受了SaltoXT翻修假体的手术。其中三个被修改(1个融合和2个新的假体),和3例患者再次手术拔除螺钉。对13例患者进行了距下融合,这些手术后有1例可能发生骨不连,但没有重复操作。5年后,平均AOFAS评分从术前的39.2(95%CI30.8-47.5)增加到75.1(95%CI67.3-82.9),平均改善为34.2点(95%CI23.8-44.6)。5年后,平均EQ-5D从术前的0.36(95%CI0.30-0.42)增加到0.74(95%CI0.64-0.85),改善0.34(95%CI0.19-0.49)。除3例患者外,所有患者均存在射线可透线。5年假体生存率为93%(83.6-100)。
■这是该植入物的中期结果的第一项研究。我们发现在结果评分和良好的植入物存活率方面有很好的改善,而且射线可透线的患病率很高。